Shandong Jincheng Pharmaceutical Group Co., Ltd.

Shandong Jincheng Pharmaceutical Group Co., Ltd. faced a significant stock decline, reflecting ongoing financial challenges. The company reported a 57.9% drop in profits over the past year and a net sales decline of 1.15% annually. It operates in the Pharmaceuticals & Biotechnology sector with a market capitalization of CNY 4,448 million.

Shandong Jincheng Pharmaceutical Group Co., Ltd. has recently experienced a change in its valuation score, reflecting shifts in financial metrics and market position. The company shows a high P/E ratio and elevated Price to Book Value, while facing challenges in return on equity and sales growth over recent years.

Shandong Jincheng Pharmaceutical Group Co., Ltd. has recently experienced a change in its evaluation due to shifts in financial metrics and market conditions. The company, classified as midcap in the Pharmaceuticals & Biotechnology sector, faces challenges reflected in its technical indicators and recent financial performance.

Shandong Jincheng Pharmaceutical Group Co., Ltd. faced a notable decline in stock performance, significantly underperforming the China Shanghai Composite. The company has experienced consistent decreases over various time frames, with financial indicators highlighting challenges such as reduced net sales and low operating cash flow, raising concerns about its valuation.

Shandong Jincheng Pharmaceutical Group Co., Ltd. saw a notable stock decline on March 3, 2026, contrasting with the broader market. The company has faced ongoing challenges, including a significant drop in net sales and low operating cash flow, contributing to a substantial decline in long-term stock performance.